Scarica l'app Stockscreener
1.205
2.82%
-0.035
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché JAGX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.24
Aprire:
$1.27
Volume 24 ore:
39,704
Relative Volume:
0.19
Capitalizzazione di mercato:
$5.03M
Reddito:
$10.48M
Utile/perdita netta:
$-37.74M
Rapporto P/E:
-0.0745
EPS:
-16.1846
Flusso di cassa netto:
$-29.03M
1 W Prestazione:
-9.40%
1M Prestazione:
-33.24%
6M Prestazione:
-62.75%
1 anno Prestazione:
-94.87%
Intervallo 1D:
$1.19
$1.27
Intervallo di 1 settimana:
$1.16
$1.50
Portata 52W:
$1.00
$33.25
Jaguar Health Inc Stock (JAGX) Company Profile
Nome
Jaguar Health Inc
Settore
Industria
Telefono
415-371-8300
Indirizzo
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Confronta JAGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAGX
Jaguar Health Inc
|
1.205 | 5.18M | 10.48M | -37.74M | -29.03M | -16.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.41 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.75 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
872.39 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.94 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
202.58 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-07-11 | Iniziato | Rodman & Renshaw | Buy |
Jaguar Health Inc Borsa (JAGX) Ultime notizie
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lubbock Avalanche-Journal
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts - Pensacola News Journal
Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF) - Hornell Evening Tribune
Jaguar Health director gets 5,870 RSUs and 5,870 options | JAGX SEC FilingForm 4 - Stock Titan
Jaguar Health submits abstract on crofelemer for short bowel syndrome By Investing.com - Investing.com Canada
Jaguar Health (JAGX) Advances Treatment for Short Bowel Syndrome - GuruFocus
Jaguar Health submits abstract on crofelemer for short bowel syndrome - Investing.com
Jaguar Health (NASDAQ: JAGX) advances crofelemer program in SBS-IF, MVID trials - Stock Titan
Jaguar Health executes strategic stock exchange agreements - MSN
Jaguar Health Executes Strategic Stock Exchange Agreements - TipRanks
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs - The Florida Times-Union
Jaguar Health Inc (JAGX) is looking forward to a strong quarter - setenews.com
Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders - Lubbock Avalanche-Journal
Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones - The Florida Times-Union
FDA extends conditional approval for Jaguar Health’s canine drug By Investing.com - Investing.com Australia
FDA extends conditional approval for Jaguar Health’s canine drug - Investing.com
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates - Bluffton Today
Jaguar Health Inc Azioni (JAGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.12%
0.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):